Denali Therapeutics (DNLI) and Royalty Pharma (RPRX) announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II. A Biologics License Application for accelerated approval of tividenofusp alfa is under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act, PDUFA, target date of April 5, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target lowered to $26 from $27 at BofA
- Denali Therapeutics: Promising Future with Tivi Approval and Unique Brain Shuttling Platform
- Denali Therapeutics: Strategic Positioning and Growth Potential with Pioneering TfR-Enabled Medicine Launch
- Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations
- Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating